期刊论文详细信息
Journal of Ovarian Research
mEH Tyr113His polymorphism and the risk of ovarian cancer development
Le-Qun Li1  Zhi-Ming Zhang1  Jian-Hong Zhong1 
[1] Department of Surgical Oncology, Tumor Hospital of Guangxi Medical University, He Di Rd. #71, Nanning 530021, P.R. China
关键词: Ovarian cancer;    Polymorphism;    Microsomal epoxide hydrolase;    Meta-analysis;   
Others  :  810466
DOI  :  10.1186/1757-2215-6-40
 received in 2013-03-29, accepted in 2013-06-03,  发布年份 2013
PDF
【 摘 要 】

Background

The causes of ovarian cancer are complex and may be influenced by many factors, including polymorphism in the microsomal epoxide hydrolase (mEH) gene. Previous work suggests an association between the Tyr113His mEH polymorphism rs1051740 and susceptibility to ovarian cancer, but the results have been inconsistent.

Methods

PubMed, EMBASE, Google Scholar, and Chinese National Knowledge Infrastructure databases were systematically searched to identify relevant studies. A meta-analysis was performed to examine the association between Tyr113His mEH polymorphism and susceptibility to ovarian cancer. Odds ratios (ORs) and 95% confidence intervals (CIs) were calculated.

Results

Five studies involving 2,566 cases and 2,839 controls were included. Although the polymorphism did not affect ovarian cancer risk in the allelic contrast model (OR = 0.99, 95% CI = 0.83-1.17, P = 0.86), the mutant CC genotype was significantly associated with increased risk in the homozygote comparison (OR = 1.20, 95% CI = 1.01-1.43, P = 0.04) and recessive genetic models (OR = 1.20, 95% CI = 1.01-1.41, P = 0.03). The wild-type TT genotype was not associated with higher or lower ovarian cancer risk in the dominant genetic model (OR = 1.04, 95% CI = 0.83-1.29, P = 0.74). These results were robust to sensitivity analysis.

Conclusions

The CC genotype of Tyr113His mEH may confer increased risk of ovarian cancer. These conclusions should be verified in large and well-designed studies.

【 授权许可】

   
2013 Zhong et al.; licensee BioMed Central Ltd.

【 预 览 】
附件列表
Files Size Format View
20140709042736416.pdf 429KB PDF download
Figure 2. 57KB Image download
Figure 1. 83KB Image download
【 图 表 】

Figure 1.

Figure 2.

【 参考文献 】
  • [1]Siegel R, Naishadham D, Jemal A: Cancer statistics, 2013. CA Cancer J Clin 2013, 63:11-30.
  • [2]Ding YC, McGuffog L, Healey S, Friedman E, Laitman Y, Paluch-Shimon S: A Nonsynonymous Polymorphism in IRS1 Modifies Risk of Developing Breast and Ovarian Cancers in BRCA1 and Ovarian Cancer in BRCA2 Mutation Carriers. Cancer Epidemiol Biomarkers Prev 2012, 21:1362-1370.
  • [3]Wu J, Cai C, Tong D, Hou H: Lysyl Oxidase G473A Polymorphism Is Associated with Increased Risk of Ovarian Cancer. Genet Test Mol Biomarkers 2012, 16:915-919.
  • [4]Ma YY, Guan TP, Yao HB, Yu S, Chen LG, Xia YJ, He XJ, Wang HJ, Jiang XT, Tao HQ: The MDM2 309T > G Polymorphism and Ovarian Cancer Risk: A Meta-Analysis of 1534 Cases and 2211 Controls. PLoS One 2013, 8:e55019.
  • [5]Chaudhary S, Panda AK, Mishra DR, Mishra SK: Association of +331G/A PgR Polymorphism with Susceptibility to Female Reproductive Cancer: Evidence from a Meta-Analysis. PLoS One 2013, 8:e53308.
  • [6]Dannan GA, Guengerich FP: Immunochemical comparison and quantitation of microsomal flavin-containing monooxygenases in various hog, mouse, rat, rabbit, dog, and human tissues. Mol Pharmacol 1982, 22:787-794.
  • [7]Hattori N, Fujiwara H, Maeda M, Fujii S, Ueda M: Epoxide hydrolase affects estrogen production in the human ovary. Endocrinology 2000, 141:3353-3365.
  • [8]Newman JW, Morisseau C, Hammock BD: Epoxide hydrolases: their roles and interactions with lipid metabolism. Prog Lipid Res 2005, 44:1-51.
  • [9]Fretland AJ, Omiecinski CJ: Epoxide hydrolases: biochemistry and molecular biology. Chem Biol Interact 2000, 129:41-59.
  • [10]Shou M, Gonzalez FJ, Gelboin HV: Stereoselective epoxidation and hydration at the K-region of polycyclic aromatic hydrocarbons by cDNA-expressed cytochromes P450 1A1, 1A2, and epoxide hydrolase. Biochemistry 1996, 35:15807-15813.
  • [11]Baxter SW, Choong DY, Campbell IG: Microsomal epoxide hydrolase polymorphism and susceptibility to ovarian cancer. Cancer Lett 2002, 177:75-81.
  • [12]Goode EL, White KL, Vierkant RA, Phelan CM, Cunningham JM, Schildkraut JM, Berchuck A, Larson MC, Fridley BL, Olson JE, Webb PM, Chen X, Beesley J, Chenevix-Trench G, Sellers TA: Ovarian Cancer Association Consortium; Australian Ovarian Cancer Study Group: Xenobiotic-Metabolizing gene polymorphisms and ovarian cancer risk. Mol Carcinog 2011, 50:397-402.
  • [13]Kang S, Duan LH, Li Y, Song JF, Zhang JH: [Relation Between microsomal epoxide hydrolase polymorphism and susceptibility to ovarian epithelial cancer]. Zhonghua Fu Chan Ke Za Zhi 2004, 39:556-557.
  • [14]Lancaster JM, Brownlee HA, Bell DA, Futreal PA, Marks JR, Berchuck A, Wiseman RW, Taylor JA: Microsomal epoxide hydrolase polymorphism as a risk factor for ovarian cancer. Mol Carcinog 1996, 17:160-162.
  • [15]Spurdle AB, Purdie DM, Webb PM, Chen X, Green A, Chenevix-Trench G: The microsomal epoxide hydrolase Tyr113His polymorphism: association with risk of ovarian cancer. Mol Carcinog 2001, 30:71-78.
  • [16]Higgins JP, Thompson SG, Deeks JJ, Altman DG: Measuring inconsistency in meta-analyses. BMJ 2003, 327:557-560.
  • [17]Harbord RM, Egger M, Sterne JA: A modified test for small-study effects in meta-analyses of controlled trials with binary endpoints. Stat Med 2006, 25:3443-3457.
  • [18]Liberati A, Altman DG, Tetzlaff J, Mulrow C, Gøtzsche PC, Ioannidis JP, Clarke M, Devereaux PJ, Kleijnen J, Moher D: The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate health care interventions: explanation and elaboration. PLoS Med 2009, 6:e1000100.
  • [19]Liu F, Yuan D, Wei Y, Wang W, Yan L, Wen T, Xu M, Yang J, Li B: Systematic Review and Meta-Analysis of the Relationship between EPHX1 Polymorphisms and Colorectal Cancer Risk. PLoS One 2012, 7:e43821.
  • [20]Li X, Hu Z, Qu X, Zhu J, Li L, Ring BZ, Su L: Putative EPHX1 enzyme activity is related with risk of lung and upper aerodigestive tract cancers: a comprehensive meta-analysis. PLoS One 2011, 6:e14749.
  • [21]Dura P, Bregitha CV, Te Morsche RH, Roelofs HM, Kristinsson JO, Wobbes T, Witteman BJ, Tan AC, Drenth JP, Peters WH: EPHX1 polymorphisms do not modify esophageal carcinoma susceptibility in Dutch Caucasians. Oncol Rep 2012, 27:1710-1716.
  • [22]Zhong JH, Xiang BD, Ma L, You XM, Li LQ, Xie GS: Meta-analysis of microsomal epoxide hydrolase gene polymorphism and risk of hepatocellular carcinoma. PLoS One 2013, 8:e57064.
  • [23]Pils D, Hager G, Tong D, Aust S, Heinze G, Kohl M, Schuster E, Wolf A, Sehouli J, Braicu I, Vergote I, Cadron I, Mahner S, Hofstetter G, Speiser P, Zeillinger R: Validating the impact of a molecular subtype in ovarian cancer on outcomes: a study of the OVCAD Consortium. Cancer Sci 2012, 103:1334-1341.
  • [24]Bolton KL, Ganda C, Berchuck A, Pharaoh PD, Gayther SA: Role of common genetic variants in ovarian cancer susceptibility and outcome: progress to date from the Ovarian Cancer Association Consortium (OCAC). J Intern Med 2012, 271:366-378.
  • [25]Nelson HD, Huffman LH, Fu R, Harris EL: Genetic risk assessment and BRCA mutation testing for breast and ovarian cancer susceptibility: systematic evidence review for the U.S. Preventive Services Task Force. Ann Intern Med 2005, 143:362-379.
  • [26]Gulden C, Olopade OI: Risk assessment and genetic testing for ovarian cancer. AJR Am J Roentgenol 2010, 194:309-310.
  • [27]Fasching PA, Gayther S, Pearce L, Schildkraut JM, Goode E, Thiel F, Chenevix-Trench G, Chang-Claude J, Wang-Gohrke S, Ramus S, Pharoah P, Berchuck A, OCAC (Ovarian Cancer Association Consortium): Role of genetic polymorphisms and ovarian cancer susceptibility. Mol Oncol 2009, 3(2):171-181.
  • [28]Jordan SJ, Whiteman DC, Purdie DM, Green AC, Webb PM: Does smoking increase risk of ovarian cancer? A systematic review. Gynecol Oncol 2006, 103:1122-1129.
  • [29]Hunn J, Rodriguez GC: Ovarian cancer: etiology, risk factors, and epidemiology. Clin Obstet Gynecol 2012, 55:3-23.
  • [30]Beral V, Doll R, Hermon C, Peto R, Reeves G: Ovarian cancer and oral contraceptives: collaborative reanalysis of data from 45 epidemiological studies including 23,257 women with ovarian cancer and 87,303 controls. Lancet 2008, 371:303-314.
  • [31]Murphy MA, Trabert B, Yang HP, Park Y, Brinton LA, Hartge P, Sherman ME, Hollenbeck A, Wentzensen N: Non-steroidal anti-inflammatory drug use and ovarian cancer risk: findings from the NIH-AARP Diet and Health Study and systematic review. Cancer Causes Control 2012, 23:1839-1852.
  • [32]Pinarbasi H, Silig Y, Pinarbasi E: Microsomal epoxide hydrolase polymorphisms. Mol Med Report. 2010, 3:723-727.
  • [33]Kiyohara C, Yoshimasu K, Takayama K, Nakanishi Y: EPHX1 polymorphisms and the risk of lung cancer: a HuGE review. Epidemiology 2006, 17:89-99.
  • [34]Pan Z, Trikalinos TA, Kavvoura FK, Lau J, Ioannidis JP: Local literature bias in genetic epidemiology: an empirical evaluation of the Chinese literature. PLoS Med 2005, 2:e334.
  文献评价指标  
  下载次数:95次 浏览次数:7次